Ana Kerguelen

Centro de Investigación Biomédica en Red — Spain

Medicine · Health Sciences

15h-index765citations30works1.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Myeloproliferative Neoplasms: Diagnosis and Treatment(21), Kruppel-like factors research(15), Acute Myeloid Leukemia Research(11), Eosinophilic Disorders and Syndromes(8), Chronic Myeloid Leukemia Treatments(4)

Publications29 total

TKI-mediated inhibition of NLRP1 inflammasome restores erythropoiesis in DBA syndrome
EMBO Molecular Medicine·2026Open Access
Therapeutic plasma exchange for myasthenia gravis, Guillain-Barre syndrome, and other immune-mediated neurological diseases, over a 40-year experience
Expert Review of Neurotherapeutics·2022· 2 cited
PLATELET TRANSFUSION REFRACTORINESS (PTR) IN A TERTIARY REFERRAL HOSPITAL
Transfusion and Apheresis Science·2021
Transfusion medicine during COVID‐19 outbreak in the hotspot of Spain
Transfusion·2020· 6 citedOpen Access
Clinico-biological characteristics of patients with myelofibrosis: an analysis of 1,000 cases from the Spanish Registry of Myelofibrosis
Medicina Clínica (English Edition)·2020· 12 cited
miR-146a rs2431697 identifies myeloproliferative neoplasm patients with higher secondary myelofibrosis progression risk
Leukemia·2020· 22 cited
Características clínico-biológicas de los pacientes con mielofibrosis: un análisis de 1.000 casos del Registro Español de Mielofibrosis
Medicina Clínica·2020· 5 cited
Prognostic risk models for transplant decision-making in myelofibrosis
Annals of Hematology·2018· 9 cited
Performance of the myelofibrosis secondary to PV and ET-prognostic model (MYSEC-PM) in a series of 262 patients from the Spanish registry of myelofibrosis
Leukemia·2017· 28 cited
Clinical characteristics, prognosis and treatment of myelofibrosis patients with severe thrombocytopenia
British Journal of Haematology·2017· 41 citedOpen Access
Optimismo en docentes universitarios
LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)·2017
Predictive factors for anemia response to erythropoiesis‐stimulating agents in myelofibrosis
European Journal Of Haematology·2016· 35 cited
Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea
Haematologica·2016· 72 citedOpen Access
Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation
Haematologica·2016· 145 citedOpen Access
Frequency and prognostic value of resistance/intolerance to hydroxycarbamide in 890 patients with polycythaemia vera
British Journal of Haematology·2015· 77 citedOpen Access
A Study of the Role of Antiplatelet Therapy in the Prevention of Thrombosis in Patients with Calr-Mutated Low Risk Essential Thrombocythemia
Blood·2015· 2 cited
Management of side effects of BCR/ABL-negative chronic myeloproliferative neoplasm therapies. Focus on anagrelide
Expert Review of Hematology·2015
Risk factors for non‐melanoma skin cancer in patients with essential thrombocythemia and polycythemia vera
European Journal Of Haematology·2015· 20 cited
Long-term results of prednisone treatment for the anemia of myelofibrosis
Leukemia & lymphoma/Leukemia and lymphoma·2015· 20 cited
Oral anticoagulation to prevent thrombosis recurrence in polycythemia vera and essential thrombocythemia
Annals of Hematology·2015· 54 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Juan Carlos Hernández‐Boluda(19), Alberto Álvarez‐Larrán(17), Francisca Ferrer‐Marín(17), Valentín García‐Gutiérrez(14), Francisco Cervantes(13), María Teresa Gómez‐Casares(10), Manuel Pérez‐Encinas(10), Arturo Pereira(9), Joaquín Martínez‐López(9), Natàlia Estrada(9), Patricia Vélez(8), Rosa Ayala(7), Beatriz Cuevas(7), María Laura Fox(7), Montse Gómez(7), Carles Besses(6), Juan Gonzalo Correa(6), Pere Barba(5), Concepción Boqué(5), Carlos Besses(5)